Congress is Loading up Buying These Stocks

In partnership with

200+ AI Side Hustles to Start Right Now

From prompt engineering to AI apps, there are countless ways to profit from AI now. Our guide reveals 200+ actionable AI business models, from no-code solutions to advanced applications. Learn how people are earning $500-$10,000 monthly with tools that didn't exist last year. Sign up for The Hustle to get the guide and daily insights.

Get the guide

🕵️‍♂️ Congress Just Bought These Stocks — Should You?

When lawmakers start loading up on stocks, it might be time to raise an eyebrow—or two. Why? Because history shows that some of the best-performing “investors” in America are the ones writing the laws 📜… coincidence? Probably not.

Welcome to a world where committee seats might just double as front-row seats to future profits. We're diving into the latest buys by U.S. Congress members, pulling apart what they know, why they bought, and what it might mean for your watchlist 🧠📈.

🧨 Why This Matters: Power Meets Portfolio

Forget Reddit—DC might be the real stock-picking subreddit. Members of Congress have access to juicy non-public intel. Think new bills, upcoming contracts, or policy shifts that directly impact businesses.

While there's a new bill nicknamed the “PELOSI Act” aiming to curb this kind of trading, don’t hold your breath—it's unlikely to pass. Until it does, these elected officials are trading like it’s 1999 (dot-com bubble energy and all).

🧠 The 5 Stocks Congress Is Buying Right Now

Let’s break it down, sip-your-coffee style.

1. Palantir Technologies (PLTR) – The Spy That Pays Me

Government contract magnet? Check. National security plug? Double check. Palantir is practically the Defense Department's data darling. Congresswoman Marjorie Taylor Greene snagged shares in April and walked away with a 50% gain in a month. Not too shabby.

Oh, and she sits on the Homeland Security Committee. Mere weeks later? Palantir lands a sweet $30M government deal 💼. Coincidence or clairvoyance?

📊 Metrics that matter:

• $30M+ gov’t contract post-buy

• Backed by reps from both parties (yes, bipartisanship still exists—just on stock buys, apparently)

🧠 Big picture: The company thrives on Uncle Sam’s tab. So when the defense budget balloons, Palantir doesn’t just eat—they feast.

2. Bitwise Bitcoin ETF (BITB) – Crypto With Congressional Blessing

You know crypto's mainstream when Senators are stacking sats. Senator Dave McCormack dropped nearly $1M into this Bitcoin ETF. Not only that, he’s a crypto insider—ex-Bridgewater money mover, now pushing legislation like the “Bitcoin Act.”

Talk about talking your book.

💬 “We need a national Bitcoin reserve,” he says. Translation: “I’d like my ETF to moon, please.”

📈 External trend: Increasing Congressional chatter around crypto regulation. If Bitcoin gets the green light from D.C., ETFs like BITB could catch the pump.

3. CACI International (CACI) – The Cybersecurity Sleeper

This isn’t your average defense stock—it’s the cybersecurity spine of the federal government. Congressman Michael McCaul dropped up to $250K into CACI while chairing committees that influence defense budgets. Convenient, huh?

🛡️ What they do: Surveillance, cyberwarfare, black ops tech—all things the government really doesn’t want in the wrong hands.

💰 Business metrics:

• $5.7B in annual revenue

• Nearly 100% from federal contracts

⚠️ Ethics alert: Investing in a company you can funnel contracts to? That’s like being a referee with money on the game.

4. Boeing (BA) – The Political Frequent Flyer

Boeing is back in the Congressional cockpit. Rep. Breahan Jr. (an absolute trading machine with 264 transactions in 2025) bought Boeing stock during dips. Oh, and he's also shaping aviation policy. Small world, right? ✈️

🌍 Tailwinds:

• Global geopolitical tension = more defense spending

• Billions in Pentagon contracts

• Post-COVID commercial flight boom

🧮 Business bounce-back: Boeing's been clawing back after supply chain hell and PR disasters. And if Congress believes in the comeback? Maybe investors should, too.

5. Transcode Therapeutics (RNAZ) – Sponsored, But Spicy

This one’s a biotech moonshot, and it’s clearly marked as sponsored—but it’s still intriguing. Transcode is tackling cancer with RNA-based nanotech, backed by Harvard research and MD Anderson collabs. Clinical trials are underway, and early animal tests showed complete regression of tumors. Not bad for a penny stock play 🧬.

💸 Capital raised: $56M through IPOs and NIH grants

⚠️ Keep in mind: This stock was featured as a sponsored segment. Read: take with a shaker of salt 🧂.

📊 Summary: What We’re Seeing

Congress loves contracts, crypto, and cancer cures. There’s a pattern here—government-backed, tech-forward, future-leaning plays. These aren’t your grandpa’s dividend stocks.

Here’s the full list for your watchlist:

⚠️ Disclaimer: Not Financial Advice

This content is for educational and informational purposes only. We are not financial advisors. Always do your own research, and consult a licensed professional before making any investment decisions.

So… should you follow Congress into these plays? That’s up to you. But one thing’s for sure: when politicians start betting millions, it might be worth watching where the chips fall 🎰.

Want a deeper dive on any of these stocks? Read Below:

Let’s pop the hood on each stock Congress is buying and break down what makes them tick—from fundamentals to political entanglements to where the puck might be heading 🕵️‍♀️📊.

🔍 1. Palantir Technologies (PLTR) – The Government’s Favorite Nerd

🧬 What They Do:

Palantir builds supercharged data platforms used by U.S. military, intelligence agencies, and homeland security. Think of them as the software backbone for national defense, disaster response, and covert ops.

📈 Key Business Metrics:

• Revenue (FY24): $2.23B, growing at 16% YoY

• Profitability: Now GAAP-profitable after years of losses (Wall Street likes that)

• Backlog: Over $1B in future government contracts

💼 Recent Wins:

• $30M contract from DHS awarded right after Marjorie Taylor Greene’s buy

• Expanding AI and LLM integration for defense and logistics

🤝 Political Perks:

• Congress members on homeland and defense committees are heavily invested

• Company uniquely positioned for new AI-fueled defense programs

• Founders (including Peter Thiel) have deep roots in Silicon Valley and D.C. alike

🚀 Why It Might Work:

Palantir is a bet on predictive data + defense spending. It’s riding the AI wave, and if the U.S. keeps beefing up military tech, PLTR could be printing more contracts than the U.S. Treasury prints dollars.

🔍 2. Bitwise Bitcoin ETF (BITB) – Crypto's New Suit-and-Tie Investor

🧬 What They Do:

BITB is an ETF that holds actual Bitcoin. It gives traditional investors (like Senators!) crypto exposure without needing cold wallets or Coinbase.

📈 Key Business Metrics:

• Assets under management (AUM): Grew from $250M → $1.1B since ETF approval in Jan 2024

• Expense ratio: 0.20% (competitive for crypto ETFs)

💼 Tailwinds:

• Spot Bitcoin ETFs approved = Wall Street stamp of approval

• Institutional inflows rising (BlackRock, Fidelity entering the chat)

🤝 Political Perks:

• Senator Dave McCormack bought $1M+ and sits on the Senate Subcommittee for Digital Assets

• He’s proposing the Bitcoin Reserve Act (yes, that’s a thing), calling for the U.S. to hold Bitcoin like gold

🚀 Why It Might Work:

You’re not just betting on Bitcoin—you’re betting that crypto gets regulatory clarity and government acceptance. If Uncle Sam starts stacking sats, this ETF could be the gateway drug.

🔍 3. CACI International (CACI) – Cybersecurity's Beltway Insider

🧬 What They Do:

CACI provides surveillance, signal processing, and cyber warfare tools—essentially digital weapons and countermeasures.

📈 Key Business Metrics:

• Revenue (FY24): $7.3B

• Net income: $473M

• Contract win rate: ~75% on new bids

💼 Recent Moves:

• New defense contracts with Army and Navy

• Investing heavily in AI-driven threat detection and battlefield data fusion

🤝 Political Perks:

• Congressman McCaul (Foreign Affairs Chair) is a top investor

• Most revenue comes from departments he oversees funding for 😬

🚀 Why It Might Work:

Cyber threats are rising, and CACI is plugged in tighter than a power strip at CES. If AI warfare becomes the next frontier, CACI’s about to get a lot more DMs (defense money).

🔍 4. Boeing (BA) – The Comeback Kid (With Fighter Jets)

🧬 What They Do:

Commercial airplanes, fighter jets, missiles, space systems. Boeing is Lockheed Martin’s dance partner—and also your airline’s supplier.

📈 Key Business Metrics:

• Revenue (FY24): $78.9B

• Backlog: $442B (yup, with a “B”)

• Profit Margin: Still recovering, but trending positive after years of losses

💼 What’s New:

• Defense contracts flowing due to Ukraine + Taiwan tensions

• Commercial plane demand rebounding post-COVID, despite production hiccups

• Infrastructure Act includes aviation upgrades = Boeing wins

🤝 Political Perks:

• Rep. Breahan Jr. buys the dip while helping craft aviation policy

• Congress lobbying for Pentagon increases in FY25

🚀 Why It Might Work:

This is a “boomer stock” with Gen Z volatility. Boeing is rebuilding trust post-737 MAX debacle, but if they stick the landing, they could fly (again). Plus, war spending is up. Boeing eats in peace and profits in conflict.

🔍 5. Transcode Therapeutics (RNAZ) – Tiny Ticker, Big Science

🧬 What They Do:

A biotech moonshot using RNA nanoparticles to treat metastatic cancer. Think of it as Uber for cancer drugs—targeted delivery directly to tumor cells.

📈 Key Business Metrics:

• Market cap: ~$30M (microcap)

• Funding raised: $56M via IPOs, equity, NIH grants

• Clinical trials: Phase 1/2 ongoing for lead drug TTX-MC138

💼 Developments:

• Partnerships with MD Anderson, Mass General

• Early human trial data shows “promising signals” (read: hope, not yet proven)

⚠️ Caveats:

• Sponsored content = take with caution - this one is being pumped in paid finance circles.

• Biotech is boom-or-bust; success could mean 10x, failure = zero

🚀 Why It Might Work:

If the data holds, this is one of those “pre-FDA approval” plays that biotech junkies love. But it’s a high-wire act—no safety net, no revenue, just upside dreams.